Pharmaceutical firms face significant risks to revenue across key markets over 2020; countries in Western Europe continue to ramp up cost containment efforts whilst the threat of pricing reform in North America ranges from possible to imminent. As a result we hold a less positive outlook for the industry versus 2019.
Providing upside to drugmakers, pharmaceutical spending continues to grow across emerging markets as a result of rising incomes and greater access to healthcare. However, protectionist policies and stringent price negotiations could dampen the promise of these new opportunities. Indeed, drugmakers will need to be aware of nuanced regional variations in order to tailor geographical strategy.
In this webinar, we provide critical analysis of the major trends and themes that we expect will impact pharmaceutical firms in 2020:
- Examination of proposed and implemented drug pricing reform in North America including the likelihood/impact of legislative bills in the US.
- 对成本控制measures in Western Europe that continue to drive our low-growth outlook.
- Our latest expectations for the impact of Brexit on pharmaceutical operations in Europe.
- Analysis of the increasing investment in healthcare in Asia, with a focus on the stellar medicine sales growth in China.
- Growing opportunities in the Middle-East including government focus on increasing pharmaceutical production and rising spending on healthcare.
Senior Analyst, Pharmaceuticals & Healthcare
Based in London, Beau specialises in the data-driven analysis of companies and developments across the pharmaceutical industry in Western Europe. This involves providing clients with insight into regional and global topics such as pricing regulation and patient accessibility to medicines. Prior to Fitch Solutions, he worked for biotechnology firms in Cambridge Science Park and BioCity Scotland in commercial analysis roles. Beau graduated from the University of Edinburgh with a master’s degree in Chemistry which included research focusing on the drug delivery applications of supramolecular cages.
THIS COMMENTARY IS PUBLISHED BY FITCH SOLUTIONS COUNTRY RISK & INDUSTRY RESEARCH and is NOT a comment on Fitch Ratings' Credit Ratings. Any comments or data are solely derived from Fitch Solutions Country Risk & Industry Research and independent sources. Fitch Ratings analysts do not share data or information with Fitch Solutions Country Risk & Industry Research.